Fulminant hepatic failure: summary of a workshop

Area of Science:

• Hepatology
• Transplantation Immunology
• Critical Care Medicine

Background:

• Fulminant hepatic failure (FHF) affects approximately 2,000 individuals annually in the US, accounting for a significant portion of liver-related deaths.
• Common causes of FHF include viral hepatitis (A, B, non-A, non-B) and drug-induced liver injury.
• FHF is characterized by severe liver injury and hepatic encephalopathy in previously healthy individuals.

Framework:

• Prognostic factors for spontaneous recovery include patient age, etiology, encephalopathy grade, prothrombin time, and serum bilirubin levels.
• Liver transplantation is a primary treatment for FHF when spontaneous recovery is improbable.
• Current 1-year survival rates for FHF liver transplants are approximately 63%.

Implementation:

• Management of FHF is complex, requiring close monitoring for infections, hemodynamic instability, and cerebral edema.
• Innovative therapeutic strategies are being explored, including cytoprotective/antiviral agents and various liver support systems.
• Extracorporeal liver support, hepatocyte transplantation, auxiliary liver transplantation, and xenotransplantation are under investigation.

Implications:

• While no novel therapies are currently proven, promising approaches aim to support patients until recovery or transplantation.
• Improved management and therapeutic interventions are crucial for enhancing survival rates in FHF patients.
• Further research into innovative treatments could significantly improve outcomes for fulminant hepatic failure.